Precision oncology implementation in a regional-based health care system: A professional consensus to define the pathway
- PMID: 39532218
- DOI: 10.1016/j.jcpo.2024.100515
Precision oncology implementation in a regional-based health care system: A professional consensus to define the pathway
Abstract
Objective: Precision Oncology requires deep changes in organizational settings but little evidence has been identified about the best strategy to guarantee the delivery of this innovation to patients. In the Italian health care system, high heterogeneity could jeopardize equal access opportunity for patients. Following a consensus method, we aim to define shared solutions to address these issues in clinical practice.
Method: A Delphi RAND method was chosen to record the consensus among involved health care professionals in the Italian region of Friuli Venezia Giulia. The item generation phase was conducted following a bottom-up approach.
Results: Ten statements were defined on the main topics that emerged from the direct observation of the current practice, focusing on Molecular Tumor Board organization, massive parallel sequencing technology application, laboratory report content and informed consensus submission. All the statements reached a strong consensus and have been shared with the health care government authorities of our region.
Conclusions: The direct observation of the current practice in different health care authorities allowed to define ten statements as solution proposals to solve the identified complexities. This methodological approach could be applied in different organizational models but aiming to achieve a homogeneous clinical outcome for patients.
Keywords: Bottom-up Approach; Delphi method; Innovation delivery; Organizational research; Precision oncology implementation; Professional consensus.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Maria Carla Barducci reports a relationship with Roche that includes: speaking and lecture fees. Giacomo Pelizzari reports a relationship with Roche that includes: speaking and lecture fees. This work was supported by an unconditioned grant collected by the Healthcare Local Authority of Friuli Centrale (ASUFC) with a public call sponsorship. The contributions were by Roche, Bayer, and Amgen. The sponsors had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
